Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 1380 results for patients and public

  1. Somapacitan for treating growth hormone deficiency in children [ID6178]

    In development [GID-TA11153] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376]

    In development [GID-TA11471] Expected publication date: 03 July 2024

    Technology appraisal guidance
    In development

  3. Fruquintinib for previously treated metastatic colorectal cancer ID6274

    In development [GID-TA11280] Expected publication date: 18 September 2024

    Technology appraisal guidance
    In development

  4. Tuberculosis (NG33)

    This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.

    NICE guideline
    Last updated
    16 February 2024
    View recommendations

    Sections for NG33

  5. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development [GID-TA11221] Expected publication date: 11 September 2024

    Technology appraisal guidance
    In development

  6. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development [GID-TA11220] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Relugolix for treating hormone-sensitive prostate cancer [ID6187]

    In development [GID-TA11141] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115]

    In development [GID-TA11370] Expected publication date: 16 October 2024

    Technology appraisal guidance
    In development

  9. Elafibranor for treating primary biliary cholangitis [ID6331]

    In development [GID-TA11378] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Selpercatinib for treating advanced thyroid cancer with RET alterations (MA review of TA742) [ID6288]

    Awaiting development [GID-TA11398] Expected publication date: 13 November 2024

    Technology appraisal guidance
    Awaiting development

  11. Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]

    In development [GID-TA10977] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]

    In development [GID-TA11397] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Burosumab for treating X-linked hypophosphataemia in adults [ID3822]

    In development [GID-TA10733] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]

    In development [GID-TA11090] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]

    In development [GID-TA11384] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development